EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Therapy‐Induced ECM Remodeling Creates a Transient Immune Barrier in Residual Melanoma

Chia-Hsin Hsu iD, Jingyi Chen iD, Keng-Jung Lee iD, Leanne R Donahue iD, Danielle Kacaj, Sean P McDonough, Andrew C White iD

Advanced Science · 2025-11 · 12 (42)

DOI: 10.1002/advs.202508451 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, online erschienen am 22.08.2025. Verfasst von Chia-Hsin Hsu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Sciences, Cornell University, Ithaca, NY, 14853, USA. Hauptthemen laut MEDLINE: Extracellular Matrix, Melanoma. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Targeted therapies reshape the tumor not only by eliminating malignant cells but also by altering the stromal and immunologic adaptations that emerge during treatment, which remain incompletely defined. Here, extracellular matrix (ECM) remodeling is identified as a key driver of immune exclusion during the residual disease phase—a transient, therapy‐tolerant state that precedes overt resistance. Using an immune‐competent melanoma model and temporal transcriptomic profiling of tumor cells and fibroblasts, a coordinated induction of ECM‐related genes, particularly collagen, is uncovered during the development of residual disease. This remodeling creates a physical barrier that spatially excludes CD8⁺ T cells from residual tumor niches, compromising immune surveillance. Human melanoma datasets validate increased ECM gene expression and show an inverse correlation between collagen and cytotoxic T lymphocyte infiltration, as well as patient survival. Strikingly, pharmacologic inhibition of collagen deposition, administered at the point of maximal tumor regression, restores CD8⁺ T cell infiltration and delays resistance in a CD8⁺ T cell–dependent manner. These findings define residual disease as a therapeutically actionable stromal state and demonstrate that ECM modulation can overcome immune exclusion, thereby improving the durability of targeted therapy responses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Extracellular MatrixMelanomaHumansAnimalsMiceTumor MicroenvironmentCD8-Positive T-LymphocytesCell Line, TumorCollagen

Stichwörter der Autor:innen

BRAF/MEK inhibitorsCD8+ T cellsECMcollagenmelanomaresidual diseasetherapy resistance

Substanzen

Collagen

Autor:innen und Institutionen

  • Department of Biomedical Sciences, Cornell University, Ithaca, NY, 14853, USA.
  • Department of Biomedical Engineering, Carnegie Mellon University, Pittsburgh, PA, 15205, USA.
  • Department of Population Medicine and Diagnostic Sciences, Cornell University, Ithaca, NY, 14853, USA.

ORCID-Profile: Chia-Hsin Hsu, Jingyi Chen, Keng-Jung Lee, Leanne R Donahue, Andrew C White

Zitieren

APA

Hsu, C. H., Chen, J., Lee, K. J., Donahue, L. R., Kacaj, D., McDonough, S. P., & White, A. C. (2025). Therapy‐Induced ECM Remodeling Creates a Transient Immune Barrier in Residual Melanoma. Advanced Science, 12(42). https://doi.org/10.1002/advs.202508451

Vancouver

Hsu CH, Chen J, Lee KJ, Donahue LR, Kacaj D, McDonough SP, et al. Therapy‐Induced ECM Remodeling Creates a Transient Immune Barrier in Residual Melanoma. Advanced Science. 2025;12(42). doi:10.1002/advs.202508451

BibTeX
@article{Hsu2025,
  author = {Hsu, Chia-Hsin and Chen, Jingyi and Lee, Keng-Jung and Donahue, Leanne R and Kacaj, Danielle and McDonough, Sean P and White, Andrew C},
  title = {Therapy‐Induced ECM Remodeling Creates a Transient Immune Barrier in Residual Melanoma},
  journal = {Advanced Science},
  year = {2025},
  volume = {12},
  number = {42},
  doi = {10.1002/advs.202508451}
}
Kostenlos starten →